These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Ivashko IN; Kolesar JM Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495 [TBL] [Abstract][Full Text] [Related]
26. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Sweis RF; Luke JJ Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141 [TBL] [Abstract][Full Text] [Related]
27. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601 [TBL] [Abstract][Full Text] [Related]
28. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697 [TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. McDermott J; Jimeno A Drugs Today (Barc); 2015 Jan; 51(1):7-20. PubMed ID: 25685857 [TBL] [Abstract][Full Text] [Related]
30. Immunotherapy: Who Is Eligible? Wang D; Gilbert J; Kim YJ Otolaryngol Clin North Am; 2017 Aug; 50(4):867-874. PubMed ID: 28755708 [TBL] [Abstract][Full Text] [Related]
32. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
33. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
34. The expanding role of immunotherapy. Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560 [TBL] [Abstract][Full Text] [Related]
35. Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood. Naito Y; Osa A; Masuhiro K; Hirai T; Koyama S; Kumanogoh A J Vis Exp; 2020 Feb; (156):. PubMed ID: 32090985 [TBL] [Abstract][Full Text] [Related]
36. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related]
37. [Pembrolizumab for the treatment of melanoma: updates and perspectives.]. Chiarion Sileni V; Mandalà M; Queirolo P Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903 [TBL] [Abstract][Full Text] [Related]
39. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416 [TBL] [Abstract][Full Text] [Related]
40. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. van Dam LS; de Zwart VM; Meyer-Wentrup FA Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]